Merck Says Experimental Hepatitis C Treatment Shows 95% Cure Rate

By Lisa Beilfuss 

Merck & Co. said Friday that its experimental drug combination for treating chronic hepatitis C patients demonstrated a 95% effective rate in a late-stage study.

The study combined grazoprevir and elbasvir in a once-daily tablet and was administered to previously untreated patients, some of whom also had HIV and liver cirrhosis, for 12 weeks.

"Patients with co-morbidities and varying treatment experiences represent important segments of the chronic hepatitis C population in need of additional innovative treatment options," said Dr. Eric Lawitz, vice president at the Texas Liver Institute.

A Merck spokesperson said the company remains on track to submit a New Drug Application with the U.S. Food and Drug Administration in the first half of 2015.

The combined tablet from Merck poses a potential threat to Gilead Sciences Inc.

Also on Friday, Gilead announced results from a midstage study that combined its blockbuster drugs Harvoni and Sovaldi to treat patients with advanced liver disease. Its study showed an 86% effective rate in pretransplant patients, and a 96% cure rate in post-transplant noncirrhotic patients with recurrent hepatitis C.

The two drugs represented more than half of Gilead's 2014 revenue.

Write to Lisa Beilfuss at [e-mail]

Access Investor Kit for Gilead Sciences, Inc.

Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US3755581036

Subscribe to WSJ: http://online.wsj.com?mod=djnwires